AGIOS PHARMACEUTICALS INC

For the period ended Dec 31, 2024. Filed Feb 13, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 13, 2025

AGIO$31.38+6.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except share and per share data) Years Ended December 31:	2024	2023	2022
Revenues:
Product revenue, net	$36,498	$26,823	$11,740
Milestone revenue	—	—	2,500
Total revenue	36,498	26,823	14,240
Operating expenses
Cost of sales	$4,165	$2,881	$1,704
Research and development	301,286	295,526	279,910
Selling, general and administrative	156,784	119,903	121,673
Total operating expenses	462,235	418,310	403,287
Loss from operations	(425,737)	(391,487)	(389,047)
Gain on sale of contingent payments	889,136	—	127,853
Milestone payment from gain on sale of oncology business	200,000	—	—
Royalty income from gain on sale of oncology business	—	—	9,851
Interest income, net	48,083	33,344	12,793
Other income, net	6,487	6,055	6,749
Net income (loss) before taxes	717,969	(352,088)	(231,801)
Income tax expense	44,244	—	—
Net income (loss)	$673,725	$(352,088)	$(231,801)
Net income (loss) per share - basic	$11.86	$(6.33)	$(4.23)
Net income (loss) per share - diluted	$11.64	$(6.33)	$(4.23)
Weighted-average number of common shares used in computing net income (loss) per share – basic	56,807,415	55,651,487	54,789,435
Weighted-average number of common shares used in computing net income (loss) per share – diluted	57,889,255	55,651,487	54,789,435

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.